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Strengths and limitations of this study
 ► We assessed all safety and efficacy postmarket-
ing authorisation referrals completed through the 
European Medicines Agency between January 2013 
and June 2017. Previous studies focused on mar-
keting authorisation withdrawal only, but we includ-
ed referrals regardless of referral outcome.
 ► While previous studies investigated which different 
evidence types are used in regulatory decision-mak-
ing, these did not look in depth at the role of these 
different evidence types, and in particular at the role 
of non-interventional evidence, which we examined 
in detail.
 ► Though the majority of studies cited in the referral 
assessment reports could be identified, occasionally 
referencing was incomplete and there was insuffi-
cient detail to determine basic study information.
 ► Judgement on the role of non-interventional ev-
idence in each assessment was to some extent 
subjective and is dependent of what is recorded in 
the assessment report. However, close agreement 
between two independent reviewers was observed.
AbStrACt
Objectives To assess the use, and evaluate the 
usefulness, of non-interventional studies and routinely 
collected healthcare data in postmarketing assessments 
conducted by the European Medicines Agency (EMA).
Design We reviewed and systematically assessed all 
referrals to the EMA made due to safety or efficacy 
concerns that were evaluated between 1 January 2013 
and 30 June 2017. We extracted information from the 
assessment report and the referral notification. Two 
reviewers independently assessed the contribution of non-
interventional evidence to decision-making.
results The preliminary evidence leading to the 
assessment in 52 eligible referrals was mostly from 
spontaneous reports (cited in 26 of 52 referrals) 
and randomised trials (22/52). In contrast, many 
evidence types were used for the full assessment. 
Non-interventional studies were frequently used in the 
full assessment for the evaluation of product safety 
(31/52) and product efficacy (18/52). In particular, non-
interventional studies were relied on for the evaluation of 
safety and efficacy in subgroups, the evaluation of safety 
relating to a rare adverse event, understanding product 
usage and misuse and for evaluation of the effectiveness 
of risk minimisation measures. The most common 
recommendations were changes to product information 
(43/52) and marketing authorisation withdrawal or 
suspension (12/52). In the majority of referrals, non-
interventional evidence was judged to contribute to the 
decision made (30/52) and in three referrals it was the 
primary source of evidence.
Conclusions European regulatory decision-making relies 
on multiple evidence types, particularly randomised trials, 
spontaneous reports and non-interventional studies. Non-
interventional studies had an important role particularly for 
the characterisation and quantification of adverse events, 
the evaluation of product usage and for evaluating the 
effectiveness of regulatory action to minimise risk.
IntrODuCtIOn
There is an ongoing public debate about the 
use of routinely collected healthcare data 
in research, particularly regarding concerns 
over patient confidentiality.1 2 Conducting 
research that meets strict confidentiality 
requirements is of paramount importance, 
but for public trust to be established and 
maintained there is also a need for evidence 
that research using patient records provides 
clear benefits for the wider public. One 
potentially important and generally agreed 
benefit is in evaluating the safety of drugs in 
real-world use, though surprisingly, there is 
no comprehensive and systematic evidence 
of how data from patient records is currently 
used in this context, with previous summa-
ries focussing largely on safety assessments 
resulting in marketing authorisation (MA) 
withdrawal or suspension.3–14
Tropical M
edicine. Protected by copyright.
 o
n
 N
ovem
ber 11, 2019 at London School of Hygiene and
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028133 on 28 October 2019. Downloaded from 
2 Brown JP, et al. BMJ Open 2019;9:e028133. doi:10.1136/bmjopen-2018-028133
Open access 
Real-world evidence has been defined in a number of 
ways. The US 21st Century Cures Act defines it as ‘data 
regarding the usage, or the potential benefits or risks, 
of a drug derived from sources other than traditional 
trials’.15 An alternative definition of real-world evidence 
is evidence derived from information collected for 
purposes other than research (ie, routinely collected 
healthcare data such as electronic healthcare records 
and insurance claims data).16 While this evidence can be 
generated by (pragmatic) randomised controlled trials, 
currently non-interventional studies are the predominant 
source of real-world evidence, and these are the focus of 
our study.16 17
Regulatory authorities increasingly require non-inter-
ventional evidence of drug effects. As a result of the US 
21st Century Cures Act, the US Food and Drug Adminis-
tration is developing a framework for the use of non-ran-
domised ‘real-world evidence’ in the approval of new 
indications and in post-authorisation medicinal product 
assessment.15 18 Similarly, the European Medicines Agen-
cy’s (EMA) adaptive pathway approach forms a new route 
of approval for medicines, blurring the lines between 
pre and postmarketing data collection, it seeks to facili-
tate conditional approval in areas of unmet need, subject 
to further evidence collection, particularly of non-ran-
domised real-world evidence.19 European Union (EU) 
legislation now mandates the assessment of medication 
effectiveness in routine clinical care where warranted.20 
The focus on using non-interventional data to evaluate 
the expected effectiveness of medicines is relatively new; 
there are concerns over their validity to measure causal 
associations, and agreed methodologies and experience 
are limited.
The aim of this study was to systematically assess the type 
of evidence used in post-authorisation drug regulation 
by the EMA to give a better understanding of the contri-
bution of non-interventional evidence and routinely 
collected data in this setting.
MethODS
We identified and reviewed all EMA post-MA referrals 
made for safety and/or efficacy concerns which were 
evaluated by an assessment committee between 1 January 
2013 and 30 June 2017. The EMA is the EU agency 
responsible for the scientific evaluation, supervision and 
safety monitoring of medicines used in the EU. Its work 
includes the evaluation of applications for MA and the 
monitoring of approved medicines. We evaluated refer-
rals which concluded after 2012 since EU medicines regu-
lation changed that year with legislation strengthening 
pharmacovigilance through many measures including 
the introduction of a Pharmacovigilance Risk Assessment 
Committee and increased regulatory requirements.21 
The evaluated referrals were made in accordance with 
the directives of European Parliament: Article 107(i) of 
Directive 2001/83/EC, Article 31 of Directive 2001/83/
EC, and Article 20 of Regulation No 726/2004 (online 
supplementary table 1).
When an EU member state or the European Commis-
sion has a significant concern regarding the safety or 
efficacy of an approved medicine, a referral process is 
initiated. The EMA initially publishes a notification, 
which details the reasons for the referral. The safety and/
or efficacy of the medicine is then assessed in depth by 
designated member states and subsequently evaluated 
by one or more of the EMA committees which include 
the Pharmacovigilance Risk Assessment Committee, the 
Committee for Medicinal Products for Human Use and 
the Co-ordination Group for Mutual Recognition and 
Decentralised Procedures-Human. Finally, an assess-
ment report is published by the EMA for each referral, 
providing information on the recommendations made 
by the assessment committee and the reasons for these 
recommendations.
Eligible referrals were identified from the EMA website. 
One reviewer (JPB) evaluated the notification and assess-
ment report of each referral using a form (available in 
the online supplementary appendix). Information was 
extracted about the notification, the referral, the medic-
inal product, the adverse events under study and the 
types of evidence assessed (preclinical, non-randomised 
trials, randomised trials, non-interventional studies, 
spontaneous reports and systematic reviews; definitions 
in online supplementary appendix). In addition, the 
reviewer assessed how different study types were used 
within the referral process and categorised usage into: 
mechanism of action, pharmacokinetics/pharmacody-
namics, efficacy, risk, product usage and the effectiveness 
of risk minimisation measures (see the online supplemen-
tary appendix for an example). The referral outcome 
was categorised into: no change, further evidence before 
decision-making, suspension or withdrawal of MA, change 
to availability and change to product information (or a 
combination of these categories).
For each referral, the adverse events under study were 
recorded and categorised into their respective Medical 
Dictionary for Regulatory Activities (MedDRA) system 
organ class.22 Drugs were categorised by Anatomical 
Therapeutic Chemical (ATC) classification system code.23
Two reviewers (JPB and IJD) independently assessed 
the recommendations made in the assessment report, 
and judged the extent to which non-interventional studies 
were both cited and contributed to the recommendation 
made, with disagreements resolved through discussion. 
We aimed to determine whether evidence from non-in-
terventional studies, and in particular, non-interventional 
studies using routinely collected data, had an important 
or pivotal role in the assessment, in order to determine 
the contribution of this type of evidence in this context.
PAtIent InvOlveMent
No patients were involved in the development of the 
research question, definition of study outcomes or study 
Tropical M
edicine. Protected by copyright.
 o
n
 N
ovem
ber 11, 2019 at London School of Hygiene and
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028133 on 28 October 2019. Downloaded from 
3Brown JP, et al. BMJ Open 2019;9:e028133. doi:10.1136/bmjopen-2018-028133
Open access
Table 1 Evidence leading to referral and evidence cited in assessment report for the 52 included referrals
Type of evidence
Evidence leading to referral* In assessment report
No of referrals
% of all 
referrals No of referrals
% of all 
referrals
Preclinical evidence 4 8 29 56
Non-randomised trials 1 2 33 63
Randomised trials 22 42 48 92
Non-interventional studies 13 25 41 79
1.Using routinely collected data 8 15 31 60
2.Using data collected for research 6 12 33 63
Spontaneous reports 26 50 38 73
Systematic review of randomised trials 7 13 27 52
Systematic review of non-interventional studies 1 2 4 8
Systematic review combining randomised trials and non-
interventional studies
0 0 8 15
Unclear 11 21 33 63
*This was primarily based on the referral notification. However, for 12 of 52 referrals, no notification was available and evidence leading to 
initiation was instead obtained from the assessment report and from the description of the referral on the EMA website.
EMA, European Medicines Agency.
design. We will disseminate our study findings to patients 
through social media and using patient groups with an 
interest in data.
reSultS
referrals
Sixty potentially eligible referrals were identified with a 
committee opinion date between 1 January 2013 and the 
31 June 2017. Of these 60 referrals, eight were excluded, 
either because they related to bioequivalence (n=4) or 
manufacturing concerns (n=3) rather than safety/effi-
cacy concerns, or because an assessment report was not 
yet available as of the 31 October 2017 (n=1) (full list of 
included referrals included in the online supplementary 
appendix).
The most frequent initiators of referrals were the Euro-
pean Commission (n=13), France (n=12), the UK (n=8), 
Germany (n=4) and Italy (n=4). According to the referral 
notification and assessment report, 21 of 52 referrals 
(40%) were made due to a combination of safety and effi-
cacy concerns, 29 (56%) due to safety concerns only and 
2 (4%) due to efficacy concerns only.
Drug groups and adverse events
The most common drug groups defined according 
to ATC code were sex hormones and modulators of 
the genital system, and analgesics (six referrals each), 
followed by drugs used in diabetes, cough and cold 
preparations, anti-inflammatory and antirheumatic prod-
ucts and cardiac therapies (three referrals each) (online 
supplementary table 2). The most common body systems 
on which referred products acted were, based on ATC 
code, the nervous system (n=13), the cardiovascular 
system (n=9), the alimentary tract and metabolism (n=8) 
and the genitourinary system and sex hormones (n=8) 
(online supplementary table 3).
The most commonly investigated adverse events 
included arterial thromboembolism (n=5), venous 
thromboembolism (n=4), hypersensitivity (n=4) and 
renal impairment (n=3). The most frequent categories 
of adverse events according to MedDRA system organ 
class were cardiac and vascular disorders (n=16); nervous 
system disorders (n=15); respiratory, thoracic and medi-
astinal disorders (n=7); and skin and subcutaneous tissue 
disorders (n=7) (online supplementary table 4).
evidence usage
Evidence cited by the initial notification and the referral 
assessment report was categorised by type (table 1). 
Where no notification was available (in 12 of 52 refer-
rals), information on the evidence leading to the 
referral was extracted from the EMA website and the 
assessment report. The evidence leading to referral was 
most commonly spontaneous reports (50%, 26/52) and 
randomised trials (42%, n=22). Assessment reports also 
frequently cited spontaneous reports (73%, n=38) and 
randomised trials (92%, n=48), but frequently cited 
non-interventional studies (79%, n=41) too. Among the 
52 referrals, in the assessment report, 31 (60%) cited 
non-interventional studies using pre-existing routinely 
collected data (eg, electronic medical records) and 33 
(63%) cited studies using data collected specifically for 
research. Evidence was also frequently cited from non-ran-
domised trials (63%, 33/52), preclinical studies (56%, 
n=29) and systematic reviews of randomised trials (52%, 
n=27). The quality of study description and referencing 
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Table 2 Number and percentage of all referrals (n=52) that use each type of evidence for each purpose
Type of evidence
Usage*
Mechanism, 
(%) PK/PD, (%)
Efficacy, 
(%)
Risk—
overall, (%)
Risk—
subgroup, 
(%)
Usage of 
product, (%)
Effectiveness of 
risk minimisation 
measures, (%)
Preclinical evidence 16 (31) 6 (12) 2 (4) 10 (19) 1 (2) 0 (0) 0 (0)
Non-randomised trials 1 (2) 10 (19) 18 (35) 14 (27) 2 (4) 0 (0) 0 (0)
Randomised trials 3 (6) 9 (17) 40 (77 36 (69) 7 (13) 0 (0) 1 (2)
Non-interventional 3 (6) 4 (8) 18 (35) 31 (60) 5 (10) 14 (27) 0 (0)
Non-interventional using 
routinely collected data
0 (0) 1 (2) 8 (15) 25 (48) 4 (8) 10 (19) 0 (0)
Non-interventional using 
data collected for research
2 (4) 4 (8) 13 (25) 20 (38) 3 (6) 7 (13) 0 (0)
Spontaneous reports 2 (4) 0 (0) 3 (6) 37 (71) 6 (12) 4 (8) 0 (0)
Systematic review of 
randomised trials
0 (0) 0 (0) 19 (37) 10 (19) 1 (2) 0 (0) 0 (0)
Systematic review of non-
interventional studies
0 (0) 0 (0) 0 (0) 4 (8) 1 (2) 0 (0) 0 (0)
Systematic review of 
randomised trials and non-
interventional studies
0 (0) 1 (2) 2 (4) 4 (8) 0 (0) 0 (0) 0 (0)
Unclear study design 1 (2) 8 (15) 12 (23) 10 (19) 0 (0) 1 (2) 0 (0)
Legend
Percentage of referrals that use evidence type for each 
purpose Colour
<10
10–19
20–29
30–39
40+
*Usage was categorised, as detailed in the table, into: mechanism of adverse event with product usage, PK/PD of product, efficacy of 
product, risk of adverse events with product, risk of adverse events with product in a subpopulation, usage/misuse of a product and 
effectiveness of regulatory risk minimisation measures.
PK/PD, pharmacokinetics/pharmacodynamic.
varied considerably by assessment report. It was not always 
possible to find a corresponding study publication or to 
ascertain the design for every study mentioned in the 
assessment; 63% (33/52) of assessment reports referred 
to at least one study of unclear design.
Table 2 summarises how each type of evidence contrib-
uted to different aspects of the assessments. The efficacy 
of medications was largely determined through evidence 
from randomised trials (cited with regard to efficacy in 
77% (40/52) of referrals), with non-interventional studies 
contributing information on efficacy in 25% (13/52) of 
assessments. Non-interventional studies contributed to 
the assessment of efficacy, to a limited degree, and mostly 
when clinical trial data were limited, such as in a subgroup 
(eg, hydroxyethyl starch in patients with trauma—EMEA/
H/A-107i/1376; intravenous nicardipine in children and 
pregnant women—EMEA/H/A-31/1339), for a product 
developed prior to current regulatory requirements (eg, 
polymyxin—EMEA/H/A-31/1383), or where a clinical 
trial would be difficult to run due to sporadic and unpre-
dictable need for therapy (eg, epinephrine autoinjec-
tors—EMEA/H/A-31/1398; methysergide for cluster 
headache—EMEA/H/A-31/1335).
For overall risks, both randomised trials (69%, 36/52) 
and non-interventional studies (60%, n=31) were 
commonly assessed, alongside evidence from spon-
taneous reports (71%, n=37). Product usage, where 
assessed, was almost entirely assessed based on non-inter-
ventional evidence (27%, n=14). Mechanistic evidence 
was largely obtained from preclinical sources (31%, 
n=16), while pharmacokinetics and pharmacodynamics 
were addressed through non-randomised trials (19%, 
n=10), randomised trials (19%, n=10) and pre-clinical 
studies (12%, n=6).
Investigation of product usage and misuse was almost 
entirely based on non-interventional data (table 2). 
Non-interventional evidence was also cited for estimating 
background incidence rates of the adverse event in the 
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Table 3 Usage of non-interventional studies in referral assessment reports
Usage of non-interventional 
studies
All referrals (n=52)
Referrals leading to MA 
withdrawal/suspension (n=12)
Referrals leading to changes to 
product information (n=43)
No of 
referrals
% of all 
referrals No of referrals % of all referrals No of referrals
% of all 
referrals
No evidence from non-
interventional studies was cited in 
the report
11 21 4 33 7 16
Evidence from non-interventional 
studies was cited, but made little 
to no contribution to the decision
11 21 4 33 9 21
The decision was consistent with 
evidence from non-interventional 
studies and also consistent with 
other evidence
27 52 4 33 24 56
The decision was consistent with 
evidence from non-interventional 
studies and this evidence was the 
primary or only factor involved 
in the decision, for example, 
there was some spontaneous 
reports and some large non-
interventional studies
3 6 0 0 3 7
MA, marketing authorisation.
population, and for characterising the prevalence of addi-
tional risk factors and effect modifiers for the outcome 
under study.
role of non-interventional evidence
Over half of the assessments relied at least in part on 
evidence from non-interventional studies to be able to 
make recommendations for regulatory action (eg, MA 
suspension or change in product information) (table 3). 
Only in 11 of 52 assessments (21%) were no non-inter-
ventional studies cited. In a further 11 referrals, non-in-
terventional studies were cited, but the reports did not 
indicate that they contributed significantly to the deci-
sion made, either because only a few pertinent non-inter-
ventional studies were cited (n=9), or due to limitations 
of the non-interventional studies (n=2).
In three referrals (combined hormonal contracep-
tives and thromboembolism; valproate, birth defects and 
developmental disorders (EMEA/H/A-31/1387); and 
Kogenate Bayer/Helixate NexGen and factor VIII inhi-
bition (EMEA/H/C/275/A20/150/EMEA/H/C/276/
A20/143) non-interventional studies alone were the 
primary source of evidence. When stratified by the 
outcome of the assessment, it appears that non-inter-
ventional evidence more often contributed to deci-
sion-making in referrals leading to prescribing changes 
(64%, 27/42) than those leading to suspension (33%, 
4/12), though only 12 assessments led to suspension or 
withdrawal of MA (table 3).
Non-interventional studies were used for the evalu-
ation of safety in a subpopulation who were largely or 
completely excluded from clinical trials, such as pregnant 
women. They were also used for estimating the risk of 
rare adverse outcomes, such as venous thromboembo-
lism with oral contraceptives, for which clinical trials were 
underpowered. Relative to spontaneous reports, non-in-
terventional studies contributed to decision-making more 
when reporting was strongly influenced by the media, 
such as with human papillomavirus (HPV) vaccines 
(EMEA/H/A-20/1421), and when the outcome was 
unlikely to be picked up by case reports, such as expo-
sure–outcome associations with a long latency period (eg, 
Caustinerf arsenical and cancer (EMEA/H/A-31/1382)). 
Non-interventional studies using routinely collected data 
were mostly used in a similar way to studies using data 
collected for research (table 2). Studies using routinely 
collected data were used more often when the outcome 
was rare, whereas studies using data collected for research 
purposes contributed more when the outcome was poorly 
recorded in clinical records (eg, Numeta G13%E/G16%E 
and hypermagnesaemia—EMEA/H/A-107i/1373).
referral outcomes
The majority (98%, 51/52) of referrals led to regulatory 
action, with the assessment committee recommending 
changes to the product information (83%, n=43) and 
particularly changes to the warnings, posology, undesir-
able effects and indication sections of the summary of 
product characteristics (table 4). In 12 of 52 (23%), refer-
rals suspension or withdrawal of MA was recommended. 
Only for one referral into the safety of HPV vaccines was 
no change recommended.
For many referrals (42%, n=22), the assessment 
committee required further specific studies to be 
conducted, generally to elucidate safety, product usage 
and the effectiveness of risk minimisation measures. From 
Tropical M
edicine. Protected by copyright.
 o
n
 N
ovem
ber 11, 2019 at London School of Hygiene and
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028133 on 28 October 2019. Downloaded from 
6 Brown JP, et al. BMJ Open 2019;9:e028133. doi:10.1136/bmjopen-2018-028133
Open access 
Table 4 Recommendations made as a result of 
assessment for the 52 included referrals
Recommendation
No of 
referrals
% of all 
referrals
No change 1 2
Further evidence before 
decision-making
2 4
Suspension or withdrawal of 
marketing authorisation
12 23
Change to availability 0 0
Change to product information 43 83
By section of the summary of 
product characteristics:
  Indication 24 46
  Posology 28 54
  Contraindications 22 42
  Warnings 39 75
  Interactions 14 27
  Pregnancy 10 19
  Driving/machinery 2 4
  Undesirable effects 26 50
  Overdose 3 6
  Studies 13 25
  Nature and contents 3 6
a review of the assessment reports and the EU register 
of post-authorisation studies (EU register), most of these 
were non-interventional studies using routinely collected 
data or data collected for research purposes (required in 
19 referrals).
DISCuSSIOn
In this comprehensive evaluation, we have shown that 
a wide range of evidence sources are used to aid deci-
sion-making during EU drug regulatory referrals. The 
three types cited in the majority of assessments were 
randomised trials, spontaneous reports and non-inter-
ventional studies. Although non-interventional evidence 
is rarely cited in notifications leading to a referral, it is 
cited substantially during the detailed assessment of most 
issues, and in a few referrals was the primary evidence type 
used in decision-making. Notably, at the end of an assess-
ment when recommendations were made for evidence 
gaps to be filled, further non-interventional evidence was 
required more often than any other type.
Each type of evidence appears to contribute to different 
aspects of a drug safety/efficacy referral, allowing for a 
well-rounded assessment of medication risks and bene-
fits. Unsurprisingly, given their unique inferential advan-
tages, randomised trials are relied on more than any 
other evidence type to provide evidence of drug efficacy. 
Current usage of non-interventional evidence for effi-
cacy largely occurs where clinical trial data are limited. 
Increasingly, however, regulators require measures of 
drug effectiveness in routine clinical care, for which 
well-designed non-interventional studies and pragmatic 
clinical trials using routinely collected data could be 
highly informative.15 19 20
To assess safety issues, non-interventional evidence is 
heavily relied on alongside randomised trials and spon-
taneous reports. Although less frequently cited, evidence 
from sources such as preclinical studies is occasionally 
relied on to provide information about mechanisms of 
effect or pharmacokinetics/pharmacodynamics.
Real-world evidence can be generated from trials, 
such as from pragmatic trials conducted using routinely 
collected data. We did not identify any such trials in the 
assessment reports. This study design could, however, be 
of considerable utility given the potential for increased 
generalisability relative to traditional trials, and the mini-
misation of confounding, through randomisation, rela-
tive to non-interventional studies.24
Strengths and limitations
We were able to assess almost all referrals completed 
between 2013 and 2017, making this the most compre-
hensive summary of recent postmarketing drug regula-
tory decision-making in Europe. The assessment reports 
are a comprehensive summary of the evidence used in 
decision-making, meaning we were able to determine 
how each type of evidence contributed to the final 
recommendations.
We were unable to directly assess the quality and 
validity of individual studies included in the assessments. 
However, by reviewing the assessment reports, we evalu-
ated how the evidence had been rated by the committees 
and how it had contributed to the overall decisions made. 
Occasionally, studies were mentioned in the assessment 
reports but no reference to a publication was given, or 
referencing was incomplete, and there was insufficient 
detail for readers to determine basic information such as 
the study design or setting. For example, for the assess-
ment report on combined hormonal contraceptives 
(EMEA/H/A-31/1356), it was not clear whether some 
of the trials mentioned were randomised or not. More 
consistent and comprehensive referencing in assess-
ment reports would increase the transparency of deci-
sion-making to the public and other stakeholders.
Judgement about how evidence was used in an assess-
ment is to some extent subjective and is also reliant on 
what is recorded in each assessment report. However, 
close agreement was achieved between the two reviewers 
in this study.
Previous studies of the role of different evidence types 
in drug regulatory decision-making have largely focused 
on MA withdrawals/suspensions.3–11 25 These studies 
highlight how the balance of evidence types has shifted 
over time, from heavy reliance on spontaneous reports 
to a more comprehensive reliance on varied evidence 
types including non-interventional studies, randomised 
controlled trials and meta-analyses. Over a similar time 
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period, the overall number of non-interventional studies 
conducted and published also appears to be increasing, 
with studies of UK electronic primary care data a prime 
example of this trend.26 With the increase in research 
opportunities provided by new database linkages this 
publication trend is likely to continue.
unique strengths of non-interventional evidence
Non-interventional evidence was particularly useful for the 
assessment of product safety in situations where evidence 
from randomised controlled trials was limited such as 
the quantification of rare events, and the investigation of 
special populations (eg, pregnant women and children). 
While other types of evidence are also useful in some of 
these areas, our study highlighted occasions when non-in-
terventional evidence is unique and vital for regulatory 
decision-making. The risk of developmental disability and 
birth defects in the offspring of women taking valproate 
in pregnancy is a key example of this.27 This rare outcome 
occurring in a group largely excluded from randomised 
trials could not have been characterised and quantified 
without large, well-powered non-interventional studies. 
Similarly, the detailed characterisation and quantification 
of adverse outcomes associated with nonsteroidal anti-in-
flammatory drugs and the oral contraceptive could not 
have been done without good quality non-interventional 
evidence. Where media interest led to stimulated sponta-
neous reporting, such as in the case of HPV vaccine and 
various adverse effects, unbiased evidence from non-in-
terventional settings was vital in providing reassurance 
of safety, enabling continued use of the vaccine with no 
further action required. Randomised trials used to justify 
licensing of medicines are simply too small to detect even 
relatively common adverse reactions. The median number 
of patients studied on a new active substance is 1708 for 
standard medicines and 438 for orphan medicines in the 
EU.28 Rare adverse reactions (such as those occurring in 1 
in 500 patients) will not have been detected as caused by 
the medicine, but such rare effects can dramatically alter 
the benefit/risk balance of the medicine.
Where the EMA’s committees call for further studies 
to be done, they frequently require non-interventional 
evidence. There is increasingly a recognition that regu-
latory action to minimise risks needs to be followed 
up to determine how effective it has been.29 Almost all 
drug regulatory action involves making changes to how 
medicines are used in routine clinical care, and to deter-
mine whether new directives are being followed requires 
evidence obtained in the routine clinical care setting. 
Patterns of drug usage and quantification or charac-
terisation of adverse events following regulatory action 
are often required; non-interventional studies will be 
important here, and though spontaneous reports may 
also be useful, they are mostly unable to give quantitative 
information.
There are three key elements required to ensure a 
successful future for non-interventional evidence within 
the framework of drug regulatory science. First, there 
are legitimate concerns regarding the use of evidence 
from non-interventional studies in drug regulation given 
the potential problems of missing data and residual 
confounding.30 Through high-quality study design, 
conduct and reporting these issues can in many cases be 
resolved.31 Second, timely evidence is needed; non-inter-
ventional studies can be conducted rapidly in response to 
emerging issues, or to measure the effectiveness of past 
regulatory action. Third, the data used in non-interven-
tional studies need to be of the highest standard. This 
includes both the quality of the data and its generalis-
ability to the population from which it comes. Data quality 
can be monitored and assured by data custodians.32 
Generalisability relies on research data being drawn 
from a representative sample of the population. Whether 
data are taken from existing medical records or newly 
collected for a specific study, this requires the majority of 
patients to consent to their data to be included. For such 
a transaction between researchers and patients to operate 
successfully, maintaining anonymity and confidentiality is 
paramount.
COnCluSIOnS
Regulatory decision-making about the safety and efficacy 
of medication in the EU relies on evidence obtained 
from a wide range of sources; most frequently from 
randomised trials, spontaneous reports and non-inter-
ventional studies. Non-interventional evidence can be 
vital for characterising and quantifying adverse drug reac-
tions, is often needed for monitoring the effectiveness of 
regulatory action to minimise risks, and in certain situa-
tions will be the only available evidence.
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